MEDICAL POT USERS FILE CLASS ACTION SUIT

A U.S. District Court in Philadelphia last Wednesday, October 21 heard the
first arguments in a class action suit challenging the federal government's
prohibition on the use of medical cannabis.

The lawsuit - Kuromiya vs. the U.S. - involves 166 plaintiffs from 49
states (the Action Class for Freedom of Therapeutic Cannabis). They claim
to represent an estimated 97 million Americans who use medicinal marijuana
to help stimulate their appetite to prevent wasting, relieve the effects of
nausea due to chemotherapy, reduce high eye pressure related to glaucoma,
or for other medical purposes.

The plaintiffs assert that the government's medical marijuana ban is
unconstitutional, and violates the first, fourth, sixth, eighth, ninth, and
10th amendments. In particular, plaintiffs claim that the prohibition
violates their rights to due process and equal protection under the law.

According to plaintiffs' attorney Lawrence Elliott Hirsch, "There can be no
more cruel and unusual punishment than to deprive a seriously ill or
disabled person of the only remedy that has been found to work."

The lead plaintiff in the suit, Kiyoshi Kuromiya, is a longtime AIDS
activist who uses medical cannabis to help control HIV-related wasting.
Kuromiya and several other plaintiffs detailed their personal experiences
using medicinal marijuana and how it has helped them deal with various
maladies. He stated that the Marinol pill, which contains a synthesized
analogue of an active ingredient of marijuana, did not work for him because
pill-taking triggered his nausea and it takes up to an hour for Marinol's
effects to kick in.

'Quite Supportive' Judge

According to a report from Hirsch, District Court Judge Marvin Katz denied
the federal government's motion to have the case dismissed on the grounds
that the government is within its rights to regulate drugs as interstate
commerce.

In response to a question from the judge, federal attorneys acknowledged
that the government does provide medical cannabis to eight patients, the
few that remain from an earlier compassionate use program. According to
Kuromiya, the presence of the compassionate use program "collapses in one
fell swoop the government's argument that marijuana is not therapeutically
effective," and "flies in the face of [drug czar General Barry] McCaffrey's
statement that there is scientific proof of the unworthiness of cannabis as
a therapeutic treatment for any condition."

Likening the situation to the unfairness of providing morphine for pain
relief to only eight people, the judge proposed a settlement in which the
federal government would enroll the plaintiffs in the cannabis
compassionate use program. The attorney for the federal government said the
proposal was costly and unacceptable. The plaintiffs' attorney will poll
the Action Class to determine whether members will accept the settlement.

Kuromiya characterized Katz as "quite supportive," and said that the Action
Class has "cleared its first hurdle." The plaintiffs will file an amendment
to their lawsuit, and the government will have 60 days to respond. Both
sides were asked by the judge to provide additional information, including
scientific data related to the medicinal use of cannabis.

Checked-by: Richard Lake